Abstract | BACKGROUND:
Chemoprevention is an option for women who are at increased risk of breast cancer (five year risk ≥1.7%). It is uncertain, however, how often women accept and complete five years of therapy and whether clinical or demographic factors predict completion. METHODS: Medical records were abstracted for 219 women whose five year risk of breast cancer was ≥1.7% and who were offered chemoprevention while attending a high risk breast clinic at the Moffitt Cancer Center. We examined the likelihood of accepting chemoprevention and completing five years of therapy, and potential clinical and demographic predictors of these outcomes, using multivariable logistic regression and survival analysis models. RESULTS: CONCLUSIONS: A substantial percentage of women at increased risk of breast cancer will decline chemoprevention and among those that accept therapy, approximately 40% will not be able to complete five years of therapy because of side effects.
|
Authors | Richard G Roetzheim, Ji-Hyun Lee, William Fulp, Elizabeth Matos Gomez, Elissa Clayton, Sharon Tollin, Nazanin Khakpour, Christine Laronga, Marie Catherine Lee, John V Kiluk |
Journal | Breast (Edinburgh, Scotland)
(Breast)
Vol. 24
Issue 1
Pg. 51-6
(Feb 2015)
ISSN: 1532-3080 [Electronic] Netherlands |
PMID | 25491191
(Publication Type: Journal Article)
|
Copyright | Copyright © 2014 Elsevier Ltd. All rights reserved. |
Chemical References |
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Anticarcinogenic Agents
(therapeutic use)
- Breast Neoplasms
(epidemiology, prevention & control)
- Carcinoma, Intraductal, Noninfiltrating
(epidemiology, prevention & control)
- Female
- Humans
- Logistic Models
- Medication Adherence
(statistics & numerical data)
- Middle Aged
- Risk
- Risk Assessment
- Survival Analysis
|